Cargando…
FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trials
PURPOSE: Fluorine-18 fluorodeoxyglucose positron emission tomography combined with computed tomography (FDG PET/CT) is the standard for staging aggressive non-Hodgkin lymphoma (NHL). Limited data from prospective studies is available to determine whether initial staging by FDG PET/CT provides treatm...
Autores principales: | Kaddu-Mulindwa, Dominic, Altmann, Bettina, Held, Gerhard, Angel, Stephanie, Stilgenbauer, Stephan, Thurner, Lorenz, Bewarder, Moritz, Schwier, Maren, Pfreundschuh, Michael, Löffler, Markus, Menhart, Karin, Grosse, Jirka, Ziepert, Marita, Herrmann, Ken, Dührsen, Ulrich, Hüttmann, Andreas, Barbato, Francesco, Poeschel, Viola, Hellwig, Dirk |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8440256/ https://www.ncbi.nlm.nih.gov/pubmed/33928400 http://dx.doi.org/10.1007/s00259-021-05348-6 |
Ejemplares similares
-
Impact of vincristine dose reduction on outcomes of patients with aggressive B-cell lymphoma treated with (R)-CHOP
por: Bewarder, Moritz, et al.
Publicado: (2023) -
Current Treatment Options in CLL
por: Bewarder, Moritz, et al.
Publicado: (2021) -
PB2104: DOSE-DENSE CHEMOTHERAPY WITH R-CHOP-14 IN OLDER ADULTS AGED ≥80 YEARS WITH DIFFUSE LARGE B-CELL LYMPHOMA
por: Christofyllakis, K., et al.
Publicado: (2022) -
Low serum albumin is an independent risk factor in elderly patients with aggressive B‐cell lymphoma: Results from prospective trials of the German High‐Grade Non‐Hodgkin's Lymphoma Study Group
por: Hohloch, Karin, et al.
Publicado: (2020) -
Protection strategy against outbreak of COVID-19 at a tertiary hematology-oncology: strengths and pitfalls
por: Kaddu-Mulindwa, Dominic, et al.
Publicado: (2021)